137 related articles for article (PubMed ID: 38181739)
1. A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma.
Pozniak J; Pedri D; Landeloos E; Van Herck Y; Antoranz A; Vanwynsberghe L; Nowosad A; Roda N; Makhzami S; Bervoets G; Maciel LF; Pulido-Vicuña CA; Pollaris L; Seurinck R; Zhao F; Flem-Karlsen K; Damsky W; Chen L; Karagianni D; Cinque S; Kint S; Vandereyken K; Rombaut B; Voet T; Vernaillen F; Annaert W; Lambrechts D; Boecxstaens V; Saeys Y; van den Oord J; Bosisio F; Karras P; Shain AH; Bosenberg M; Leucci E; Paschen A; Rambow F; Bechter O; Marine JC
Cell; 2024 Jan; 187(1):166-183.e25. PubMed ID: 38181739
[TBL] [Abstract][Full Text] [Related]
2. Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma.
Wang J; Li F; Xu Y; Zheng X; Zhang C; Hu C; Xu Y; Mi W; Li X; Zhang Y
J Transl Med; 2021 Jul; 19(1):296. PubMed ID: 34238310
[TBL] [Abstract][Full Text] [Related]
3. Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy.
Anichini A; Molla A; Nicolini G; Perotti VE; Sgambelluri F; Covre A; Fazio C; Lofiego MF; Di Giacomo AM; Coral S; Manca A; Sini MC; Pisano M; Noviello T; Caruso F; Brich S; Pruneri G; Maurichi A; Santinami M; Ceccarelli M; Palmieri G; Maio M; Mortarini R;
J Exp Clin Cancer Res; 2022 Nov; 41(1):325. PubMed ID: 36397155
[TBL] [Abstract][Full Text] [Related]
4. ZEB1 transcription factor promotes immune escape in melanoma.
Plaschka M; Benboubker V; Grimont M; Berthet J; Tonon L; Lopez J; Le-Bouar M; Balme B; Tondeur G; de la Fouchardière A; Larue L; Puisieux A; Grinberg-Bleyer Y; Bendriss-Vermare N; Dubois B; Caux C; Dalle S; Caramel J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288462
[TBL] [Abstract][Full Text] [Related]
5. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
Fröhlich A; Sirokay J; Fietz S; Vogt TJ; Dietrich J; Zarbl R; Florin M; Kuster P; Saavedra G; Valladolid SR; Hoffmann F; Flatz L; Ring SS; Golletz C; Pietsch T; Strieth S; Brossart P; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Sep; 59():102962. PubMed ID: 32861198
[TBL] [Abstract][Full Text] [Related]
6. Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance.
Yang M; Lin C; Wang Y; Chen K; Zhang H; Li W
Genome Med; 2022 Jul; 14(1):72. PubMed ID: 35799269
[TBL] [Abstract][Full Text] [Related]
7. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
[TBL] [Abstract][Full Text] [Related]
8. Evolution of delayed resistance to immunotherapy in a melanoma responder.
Liu D; Lin JR; Robitschek EJ; Kasumova GG; Heyde A; Shi A; Kraya A; Zhang G; Moll T; Frederick DT; Chen YA; Wang S; Schapiro D; Ho LL; Bi K; Sahu A; Mei S; Miao B; Sharova T; Alvarez-Breckenridge C; Stocking JH; Kim T; Fadden R; Lawrence D; Hoang MP; Cahill DP; Malehmir M; Nowak MA; Brastianos PK; Lian CG; Ruppin E; Izar B; Herlyn M; Van Allen EM; Nathanson K; Flaherty KT; Sullivan RJ; Kellis M; Sorger PK; Boland GM
Nat Med; 2021 Jun; 27(6):985-992. PubMed ID: 33941922
[TBL] [Abstract][Full Text] [Related]
9. Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms.
Gruen C; Yang HH; Sassano A; Wu E; Gopalan V; Marie KL; Castro A; Mehrabadi FR; Wu CH; Church I; Needle GA; Smith C; Chin S; Ebersole J; Marcelus C; Fon A; Liu H; Malikic S; Sahinalp C; Carter H; Hannenhalli S; Day CP; Lee MP; Merlino G; Pérez-Guijarro E
bioRxiv; 2023 Apr; ():. PubMed ID: 37333132
[TBL] [Abstract][Full Text] [Related]
10. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.
Such L; Zhao F; Liu D; Thier B; Le-Trilling VTK; Sucker A; Coch C; Pieper N; Howe S; Bhat H; Kalkavan H; Ritter C; Brinkhaus R; Ugurel S; Köster J; Seifert U; Dittmer U; Schuler M; Lang KS; Kufer TA; Hartmann G; Becker JC; Horn S; Ferrone S; Liu D; Van Allen EM; Schadendorf D; Griewank K; Trilling M; Paschen A
J Clin Invest; 2020 Aug; 130(8):4266-4281. PubMed ID: 32427578
[TBL] [Abstract][Full Text] [Related]
11. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
12. Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapy.
Dong Y; Gao Q; Chen Y; Zhang Z; Du Y; Liu Y; Zhang G; Li S; Wang G; Chen X; Liu H; Han L; Ye Y
Nat Commun; 2023 May; 14(1):2540. PubMed ID: 37137884
[TBL] [Abstract][Full Text] [Related]
13. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
14. Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma.
Zhou Z; Chen MM; Luo Y; Mojumdar K; Peng X; Chen H; Kumar SV; Akbani R; Lu Y; Liang H
Cancer Cell; 2022 Nov; 40(11):1324-1340.e8. PubMed ID: 36332624
[TBL] [Abstract][Full Text] [Related]
15. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy.
Gong X; Karchin R
Sci Rep; 2023 Jan; 13(1):950. PubMed ID: 36653470
[TBL] [Abstract][Full Text] [Related]
16. 9-Gene Signature Correlated With CD8
Yan K; Lu Y; Yan Z; Wang Y
Front Immunol; 2021; 12():622563. PubMed ID: 34220795
[TBL] [Abstract][Full Text] [Related]
17. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
[TBL] [Abstract][Full Text] [Related]
18. BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment.
Tseng HY; Alavi S; Gallagher S; McGuire HM; Hersey P; Al Emran A; Tiffen J
Pigment Cell Melanoma Res; 2024 May; ():. PubMed ID: 38725219
[TBL] [Abstract][Full Text] [Related]
19. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
Liu D; Schilling B; Liu D; Sucker A; Livingstone E; Jerby-Arnon L; Zimmer L; Gutzmer R; Satzger I; Loquai C; Grabbe S; Vokes N; Margolis CA; Conway J; He MX; Elmarakeby H; Dietlein F; Miao D; Tracy A; Gogas H; Goldinger SM; Utikal J; Blank CU; Rauschenberg R; von Bubnoff D; Krackhardt A; Weide B; Haferkamp S; Kiecker F; Izar B; Garraway L; Regev A; Flaherty K; Paschen A; Van Allen EM; Schadendorf D
Nat Med; 2019 Dec; 25(12):1916-1927. PubMed ID: 31792460
[TBL] [Abstract][Full Text] [Related]
20.
Ibáñez-Molero S; van Vliet A; Pozniak J; Hummelink K; Terry AM; Monkhorst K; Sanders J; Hofland I; Landeloos E; Van Herck Y; Bechter O; Kuilman T; Zhong W; Marine JC; Wessels L; Peeper DS
Oncoimmunology; 2022; 11(1):2139074. PubMed ID: 36465485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
